

**Office of Strategy Management** 

# BALANCED SCORECARD ACCOMPLISHMENT AND COMPARATIVE SUMMARY REPORT

January – December 2023













#### PHILIPPINE HEART

#### **STRATEGY MAP 2019-2022**

VISIÚN

The Philippine Heart Center is the leader in upholding the highest standards of cardiovascular care, a self reliant institution responsive to the health needs of the Filipino people by 2022

Impact

Strategic Position

Process Core

Process Support

Better health outcomes in Cardiovascular diseases and Responsive Health System

**Healthier Filipino Hearts** 

**Position Philippine Heart Center as the** 

country's lead advocate in the prevention of

cardiovascular diseases

Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks

Provide comprehensive and responsible patient care using multi-disciplinary best practice standards

Provide comprehensive

**Employee Career training and** 

progression pathway to

enhance employee

engagement

Expand local and international training for advanced cardiovascular procedures

Promote heartfelt

cardiovascular care

experience

through positive patient

Upgrade hospital facilities for positive practice environment and stakeholders' satisfaction

policies

Provide technology solutions to improve operational efficiency

Prioritize institutional Strengthen linkages with research on advanced stakeholders for prevention cardiovascular procedures and treatment of CV to impact national health diseases nationwide

Ensure prudent and efficient asset management

**MISSION** We shall provide comprehensive cardiovascular care enhanced by education and research that is accessible to all

**CORE VALUES**  Patient-Focused Care | Compassion Integrity | Respect | Excellence

Approved by:

JOEL M. ABANILLA, MD Executive Director, PHC



**IMPACT** 

STRATEGIC POSITION

### PHILIPPINE HEART CENTER STRATEGY MAP 2023-2028

"Towards People Centered Cardiovascular Care for the Filipinos" (Bawat Pilipino, Ramdam ang Alaga sa Puso)

### Vision }

The Philippine Heart Center is the leader in upholding the highest standards of cardiovascular care, a self-reliant institution responsive to the health needs of the Filipino people by 2028

**BETTER HEALTH OUTCOMES AND INCREASED ACCESS TO CARDIOVASCULAR CARE IN THE COUNTRY** 

**HEALTHIER FILIPINO HEARTS Responsive Health System / Improved Financial Risk Protection** 

Position PHC as the enabler of the National Cardiovascular Healthcare Provider Network towards Universal Health Care Implementation by 2028

Promulgate a responsive and advanced people-centered Cardiovascular Care services in the country that treats more at less cost

Establish cardiovascular training and education of medical, nursing, ancillary, and allied specialists in Regional Heart Centers while forging international linkages

**Engage in collaborative** research with Regional Health Centers and other stakeholders and create a **National CV Disease Clinical Decision Tool and Referral Network System** 

**Empower barangay health** workers as advocates of cardiovascular wellness in the entire Quezon City, and rural health workers on RF-RHD prevention and control.

Institutionalize a Safe Hospital Culture at par with the global standards of care shared with other RHCs

Upgrade capabilities of support services to be at par with international standards

Mission }

We shall provide comprehensive cardiovascular care enhanced by education and research that is accessible to all

Values

Core | PATIENT-FOCUSED CARE | COMPASSION INTEGRITY | RESPECT | EXCELLENCE

Approved by:

Executive Director, PHC

CORE PROCESS

SUPPORT PROCESS

					IMPACT					
	Impact Indicator	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
A	Healthier Filipino	1	National Cardiac (Heart) Mortality Rate	<b>18.5</b> % (PSA: 2021)	18.0%	18.3 (124, 679,7 (PSA: 2023	. <u>182</u> 766)	18.3% (124,182 679,766) (PSA: 2023: Jan-Jul)	18.3% (124,182 679,766) (PSA: 2023: Jan- Jul)	<b>98.5%</b> (18.0/ 18.3)
	Hearts	2	Health Outcomes RHCs Mortality Z-Benefit Cardiac Surgery	10.3% (4/39)	10.0%	<b>0</b> % (0/27)		<b>0</b> % (0/27)	<b>3.4</b> % (3/114)	<b>293.04</b> % (10/3.4)
	Better Health Outcomes	3	Health Outcomes of PHC Net Overall Mortality Rate	<b>6.5%</b> (592/ 9,089)	6.2%	<b>5.1</b> (374/7	. •	<b>5.6</b> % (648/11,525)	<b>5.5</b> % (858/15,711)	113.5% (6.2/5.5)
В		Health	4	Decrease mortality from Cardiovascular disease	<b>8.2%</b> (410/4,974)	7.8%	<b>8.0</b> 2 (319/3		<b>8.46</b> % (319/3,979)	<b>9.24</b> % (671/7,265)
		5	Hospital Acquired Infection Rate	0.43% (39/ 9,089)	1.0%	<b>0.46</b> (34/7		. <b>65</b> % (67/10,316)	<b>.64</b> % (93/10,316)	155.9% (1/.64)
С	Responsive Health Systems	6	% of Respondents who gave an Outstanding Rating	80.% (base on target DOH DM2023- 0124)	80.0%	<b>92.</b> 9 (9 <b>,</b> 947/		<b>93.3</b> % (14,953/16,0 30)	<b>95.8</b> % (19126/20406)	<b>117.2%</b> (93.3/ 80)

#### STRATEGIC GOAL

				JIKAIL	SIC SOA	_				
	Goal	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
С	Responsive Health Systems	7	% NBB-Eligible patients with zero	<b>98.0</b> % (1,488/ 1,518)	98.5%	<b>96.6</b> (917/		<b>96.1</b> % (1468/152 8)	<b>95.8</b> % (1929/201 3)	<b>97.30%</b> (95.8/ 98.5)
D	Position Philippine Heart Center as the leader in cardiovascular care at par with global benchmarks	8	Number of cardiovascular procedures with health outcomes at par or better than global benchmarks	12	14	18	3	19	16	<b>114.3</b> % (16/14)
E	Position Philippine Heart Center as the country's lead advocate in the prevention of cardiovascular diseases	9	Number of PHC research/ programs on prevention adopted as national policy	5	6	5		5	5	<b>83.3</b> % (5/6)

CO	$\mathbf{D} =$	$DD\ell$		raa.	
	R E		7 J. S	• L44	

	CORE PROCESSES									
	Objective	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
	Provide comprehensive and responsible	10	No. of clinical pathways developed and implemented	24	26	<b>2</b> (28/		<b>28</b> (28/28)	<b>28</b> (28/28)	<b>112.0</b> % (28/26)
F	patient care using multi- disciplinary best practice standards	11	Percentage compliance to approved clinical pathways	52.0% (225/433) CABG: 32.1% (86/268) VSD: 87.2% (68/78) TOF: 81.6% (71/87)	70.0%	<b>61.4</b> % (239/392)		<b>59.5</b> % (369/592)	<b>59.6</b> % (473/793)	<b>91.8%</b> (59.6/65)
	Expand local and	12	Number of new training programs developed	21	23	<b>3</b> . (35/		<b>35</b> (35/23)	<b>35</b> (35/23)	<b>152.2%</b> (35/23)
G	international	13	Number of graduates of new Fellowship training programs	1. Pedia Cardio Clinical Research Fellowship 1 ongoing 2. CV Surgery Clinical Research Fellowship (Advance Aortic Surgery) 1 ongoing	2/ program	2/ program	2/ progra m	2/ program	2/ program	<b>100.0%</b> (2/2)

#### **CORE PROCESSES**

	Objective	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
	Prioritize institutional research on	14	Number of research outputs published & presented	<b>81.4%</b> (70/86)	85.0%			60.3% (41/68)	76.5% (52/68)	90% (76.5%/85 %)
н	advanced cardiovascula r procedures to impact national health policies	15	Number of research outputs completed for policies on prevention and benchmark procedures	21	23			55	66	287.0% (66/23)
	Strengthen linkages with stakeholders for prevention	16	Number of independent regional heart centers	5 1.SPMC 2.VSMMC 3.NMMC 4.WVMC 5. BRHMC 6. MMMH	6	5 (5/ (Target: 5	<sup>′</sup> 6)	<b>6</b> (6/6) (Target: 6- Jan- Sept)	<b>6</b> (6/6) (Target: 6- Jan- Dec)	<b>100%</b> (6/6)
	of CV diseases nationwide	17	Beneficiaries of barangay-based PhilPrevent program	2 1. Sitio Ruby 2 <sup>nd</sup> Phase Intervention 2. Taguig- RFRHD 3. Iloilo- RFRHD	54	54	4	81	129	<b>238.9</b> % (129/54)

#### **SUPPORT PROCESSES**

	Objective	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
	Provide comprehensive Employee Career training and progression pathway to enhance employee engagement	18	Percentage increase in employment satisfaction survey	98.4% (1,653 1,680)	92.0%	<b>193.7%</b> (505/519)		<b>293.7</b> % (892/906)	<b>393.7</b> (1044/1058)	<b>427.9</b> (393.7/92)
J		19	Percentage of filled additional plantilla positions	<b>78.1</b> % (25 32)	82.0%	<b>190.0</b> % (436/460)		<b>95.3</b> % (657/ 690)	<b>95.8</b> % (880/919)	<b>114%</b> (95.8/84)
		20	PRIME-HRM Level	<b>75.0</b> % (75/100	100.0%		<b>0</b> % /100)	<b>100</b> % (100/100)	<b>75%</b> (100/100)	<b>75.%</b> (75/100)
K	Promote heartfelt cardiovascular care	21	Percentage of resolved documented complaints	100.0% (60 60)	100.0%		<b>0</b> % /53)	1 <b>00</b> % (89/89)	100% (138/138)	<b>100</b> % (100/100)
	through positive patient experience	22	Decrease in patient safety related incidences	0.26% (96 205,818)	0.50%		<b>7%</b> 15,311)	<b>0.76</b> % (135/178,51 1)	2.09% (166/137,15 0	<b>240.7%</b> ( <u>0.87</u> 2.09)

#### **SUPPORT PROCESSES**

	Objective	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC
L	Upgrade hospital facilities for positive practice environment and stakeholders' satisfaction	23	Percentage of infrastructure projects completed as scheduled	1 <b>47.9</b> % ( <u>71</u> 48)	95.0%		. <b>0</b> % 1 20.3%)	<b>94.4</b> % (17/18: 99.42%)	<b>122.2</b> % (22/18)	128.7% (122.2/95)
М	Provide technology solutions to improve operational efficiency	24	Number of new IT systems utilized by end-users	42	50	2	27	42	55	<b>110.3%</b> (55/50)

	SUPPORT PROCESSES											
	Objective	#	Measure	BL	Target	Actual Q1	Actual Q2	Actual Q3	Actual Q4	% ACC		
		2 5	Percentage increase in Gross Revenue	41.5% (908.5M 2.2B) as of Nov 2021	10.0%	14.5 ( <u>297,73</u> 2, 110 As of June	<u>35 М</u> 9 В)	26.33% ( <u>766,609 M</u> 3, 679 B) As of Sept. 2023	27.87% (4,028 B 5,151 B) As of Dec 2023	278.69% (27.87/10.)		
N	Ensure prudent and efficient asset	2 6	Budget utilization rate	<b>78.3</b> % (1.6B 2.1B)	85.0%	<b>62.1</b> ( <u>864,4</u> 1,392 As of June	<u>48M</u> 2B)	67.20% (1,404 B 2,089 B) As of Sept. 2023	<b>75.20</b> % ( <u>2,094 B</u> 2,785 B) As of Dec 2023	<b>88.46</b> % (75.2/85)		
	management	2 7	CapEx budget utilization rate	32.1% (90.8M 282.6 M	85.0%	<b>4.8</b> ° ( <u>4,88</u> 101,04	<u>9M</u>	<b>34.4</b> % ( <u>52,113 M</u> 151,572 M)	<b>41.2</b> % ( <u>83,293 M</u> 151,572 M)	48.5% (41.2/85.5)		
		2 8	Zero out-of-stock essential drugs and supplies	<b>6.1</b> % ( <u>5.6</u> 92)	5.5%	NO REF	PORT	<b>6.28</b> % ( <u>5.8</u> 92)	<b>5.53</b> % ( <u>5.8</u> 92)	<b>99.5</b> % (5.53/5.5)		



## **Balanced Scorecard 2023 Summary Report**



PERSPECTIVE	Jan – December 2023
SOCIAL IMPACT (1-7 measures)	137.1%
ORGANIZATION (8-9 measures)	98.8%
INTERNAL PROCESS (10-11, 20-24 measures)	123.1%
PEOPLE EMPOWERMENT (12-19 measures)	141.1%
FUND RESOURCE (25-28 measures)	128.7%
AVERAGE ACCOMPLISHMENT	125.8%  Outstanding







# **Balanced Scorecard** 4<sup>th</sup> Quarter 2022 vs 4<sup>th</sup> Quarter 2023 Summary Report



PERSPECTIVE	January - December 2022	January - December 2023	Variance
SOCIAL IMPACT (1-7 measures)	154.3%	137.1%	-17.21%
ORGANIZATION (8-9 measures)	107.2%	98.8%	-8.36%
INTERNAL PROCESS (10-11, 20-24 measures)	103.9%	123.1%	19.16%
PEOPLE EMPOWERMENT (12-19 measures)	128.9%	141.1%	12.23%
FUND RESOURCE (25-28 measures)	100.2%	128.7%	28.57%
AVERAGE ACCOMPLISHMENT	118.9% Outstanding	125.8% Outstanding	6.9%

• 69% and below



# Balanced Scorecard 4th Quarter 2022 vs 4th Quarter 2023 Summary Report



	IMPACT	2022	2023	Variance
1	National Cardiac (Heart) Mortality Rate	97%	98.5%	1.4%
2	Health Outcomes of Regional Heart Centers Z-Benefit Cardiac Surgery Mortality rate	370%	293.0%	-77.0%
3	Health Outcomes of PHC Net Overall Mortality Rate	119%	113.5%	-5.6%
4	Decrease Mortality Rate from Cardiovascular Disease	111%	84.5%	-26.9%
5	Hospital Acquired Infection Rate	192%	155.9%	-36.0%
6	% of Client with Very Satisfactory Rating	93%	117.2%	24.0%
7	% No Balance Billing	98%	97.3%	-0.4%
	Average	154.3%	137.1%	-17.21%

	ORGANIZATION	2022	2023	2021
8	Number of cardiovascular procedures with health outcomes at par or better than global benchmarks	114.3%	114.3%	0.0%
9	Number of PHC research/ programs on prevention adopted as national policy	100.0%	83.3%	-16.7%
	Average	107.2%	98.8%	-8.4%







	IMPACT	2022	2023	Variance
12	Number of new training programs developed	152.2%	152.2%	0.0%
13	Number of graduates of new Fellowship training programs/Hospitals with completed module	100.0%	100.0%	0.0%
14	Number of research outputs Presented/Published	114.8%	90.0%	-24.8%
1 15	Number of research outputs completed for policies on prevention and benchmark procedures	191.3%	287.0%	95.7%
16	Number of Independent Regional Heart Centers	100.0%	100.0%	0.0%
17	Beneficiaries of barangay-based PhilPrevent program	100.0%	179.2%	79.2%
18	% Increase in employment satisfaction survey	150.6%	107.0%	-43.6%
19	Percentage filled additional plantilla positions	122.0%	113.5%	-8.5%
	Average	128.9%	141.1%	12.2%



# Balanced Scorecard 4th Quarter 2022 vs 4th Quarter 2023 Summary Report




	INTERNAL PROCESS	2022	2023	VARIANCE
10	No. of Clinical Pathways developed and implemented	112.0%	112.0%	0.0%
11	% Compliance rate to approved Clinical Pathways	118.6%	91.8%	-26.8%
20	PRIME-HRM Level	100.0%	75.0%	-25.0%
21	% of Resolved documented complaints	98.9%	100.0%	1.1%
22	Decrease in patient safety-related incidences	0.57%	240.66%	240.1%
23	% of infrastructure projects completed as scheduled	186.4%	128.7%	-57.7%
24	Number of new IT systems utilized by end-users	111.0%	113.5%	2.5%
	Average	103.9%	123.1%	19.2%

	FUND RESOURCES	2022	2023	VARIANCE
25	% Increase in gross revenue	208.9%	278.69%	69.78%
26	Budget utilization rate	99.8%	88.46%	-11.34%
27	CapEx budget utilization rate	22.9%	48.20%	25.30%
28	Zero out-of-stock essential drugs and supplies	69.0%	99.54%	30.54%
	Average	100.2%	128.7%	28.57%









	CARDIOVASCULAR PROCEDURES	BENCHMARK	PHC 2018-2023	Office Responsible
2017	Device Closure of Congenital Heart Disease-PDA	0% Morbidity (Cleveland Clinic 2015: 42 cases)	<b>0.76</b> % (8/1049 cases)	DPC- Invasive Cardiology; DAC- Invasive
	Atrial Septal Defect Repair	0%, (42 cases)	1.14% ( 6/528)	DSA- Surgery
	PCI Door to Wire Time	90 minutes	<b>Not monitored</b> (CV Lab only)	DAC- Invasive Cardiology DAEC- ER
2010	Percutaneous Transmitral Commissurotomy	< 1% (Phil. Society of CV Catherization Inc)	<b>0</b> % (0/321)	DAC- Invasive Cardiology
2018	Close Follow-up of Discharged Patients through Telecare Nursing (Focus on post-reportable outcomes after 30 days)	Not Available		Nursing - Telecare
	Minimally Invasive Cardiac Surgery	0% (Cleveland Clinic, 256 Procedures)	3.24% (7/216)	DSA- Surgery
	Device Closure of Congenital Heart Disease-ASD (Adult + Pedia)	3%	<b>0</b> % (0/138)	DPC- Invasive Cardiology : DAC Invasive
2019	Device Closure of Congenital Heart Disease-VSD	3%	<b>0</b> % (0/124)	DPC- Invasive Cardiology
	Single Valve Repair	Mitral-5.8% ( Society of Thoracic Surgeons)	3.39% (37/1093)	DSA- Surgery
		Aortic-3.8% ( Society of Thoracic Surgeons)	5.29% (/18/340)	DSA- Surgery
	Transcatheter Aortic Valve Replacement	5.2% ( Society of Thoracic Surgeons, 2015)	4.44% (2/45)	DSA- Surgery
2020	Endovascular Aneurysm Repair	6.1% (American Heart Association)	5.71% (8/140)	DSA- Vascular Surgery
	Advanced Heart Failure Therapies			DAEC- Critical Care Division
	Best Practice in Blood Conservation			DAMS- Bloodbank
	Advanced Coronary Revascularization			DAC- Invasive Cardiology
2021	Radio Frequency Ablation Therapy	<2%	2.24% ( 14/610)	DAC- EPS
	Cardiovascular Clinical Trial Center			ETRS- Clinical Research
	Arterial Switch Operation	11% (World Database)	20.19% (37/196)	DPC- Clinical & Critical
2022	Neonatal Cardiac Surgery	20% (World Database)	28.97% (48/193)	DPC- Clinical & Critical
	Peripheral Endovascular Revascularization	< 1% (American Heart Association, 2017)		DSA- Vascular Surgery

Legend: Outcomes at par with global standards

	NATIONAL POLICIES	Office Responsible
201 <i>7</i>	Policy on Health Facility Development of Regional Hospitals for Cardiac Specialty to Ensure Availability of Cardiovascular Care in 17 Regions (DOH)	Corp Plan (OSM)
2017	Full Treatment of Rare Kawasaki Disease with IVIG for the Prevention of Coronary Aneurysm (Registry, Free IVIG DOH)	DPC
2018	Philhealth Special Benefit (Free) Secondary Prophylaxis for all RFRHD Patients 5 to 25 years old	DPC
2019	Philhealth Z-Benefit for Primary PCI in STEMI	DAC- Invasive Cardiology
	Adoption of Employees' Wellness Program for all National Government Agencies	ETRS- Preventive Cardiology
2020	Philhealth Z-Benefit Coverage for Mitral Valvuloplasty	DSA/DAC
	Mandatory Neonatal Pulse-Oximetry in Newborns for Early Detection of Critical Congenital Heart  Disease as part of Philhealth-covered Newborn Screening	DPC
2021	Mandatory Screening for all Grade 6 Students for Early Detection of Metabolic Syndrome for Cardiovascular Risk Reduction in Children	DPC
2021	Philhealth Z-Benefit Coverage for PDA Device Closure	DPC
2022	Philhealth OPD Package -Mandatory Cardiovascular Risk Screening for CAD for ages 40-45 years old	

Prepared by

**GILBERT E. PENDRE** 

Planning Officer II

Office of Strategy Management

Noted by:

JULIET J. BALDERAS, MD, MSPH

OIC - Department Manager III

Management Services Department

CRISELLE M. GALANG, RN, DNM

Deputy Executive Director Nursing Services

JOSEPHINE M. GUILLERMO-LOPEZ, CPA, MBA

Deputy Executive Director Hospital Support Services MARIA TERESA B. ABOLA, MD

Deputy Executive Director

Education, Training and Research Services

**GERARDO S. MANZO, MD** 

Deputy Executive Director

**Medical Services** 

Approved by : **JOEL M. ABANILLA, MD** 

**Executive Director**